摘要
目的:评价不同麻醉药对瑞芬太尼诱发术后痛觉超敏的影响。方法:40只尾静脉置管成功的成年雄性SD大鼠,根据不同麻醉方式随机分为5组(n=8):七氟醚麻醉组(S组);七氟醚+瑞芬太尼复合麻醉组(S+R组);小剂量丙泊酚麻醉组(Pro组);小剂量丙泊酚+瑞芬太尼麻醉组(Pro+R组);大剂量丙泊酚+瑞芬太尼麻醉组(HPro+R组)。在不同麻醉方式下建立大鼠后足切割痛模型并维持麻醉一小时,于术前24小时以及停药后6小时,24小时,48小时测定双后足的机械痛阈(PWT)及观测以上不同时间点切割足的累积疼痛评分(CPS)。结果:S+R组与S组相比,停药后6小时切割足的CPS增加(P<0.05)、24小时双后足的PWT均下降(P<0.05)。HPro+R在停药后各时间点切割足的PWT均高于Pro组(P<0.001)、Pro+R组(P<0.01)。与Pro+R组相比,HPro+R组在停药后各时间点切割足的CPS均低于Pro+R组(P<0.05)。结论:吸入麻醉药七氟醚可加剧瑞芬太尼导致的术后痛觉过敏,而大剂量丙泊酚可抑制瑞芬太尼诱发的术后痛觉过敏。
Objective: To assess the effect of different anesthetics(sevoflurane, propofol) on remifentanil-induced postoperative hyperalgesia. Methods: Forty male adult Sprague-Dawley rats in which caudal vein catheter was successfully placed were randomly divided into 5 groups(n=8): sevoflurane anesthesia group(Group S), sevoflurane +remifentanil anesthesia group(Group S+R), low dose of propofol anesthesia group(Group Pro), low dose of propofol+remifentanil anesthesia group(Group Pro+R), high dose of propofol+remifentanil anesthesia group(Group HPro+R). All the rats underwent plantar incision under anesthesia with the different anesthetic ways, respectively. Paw withdrawal threshold(PWT) and cumulative pain score(CPS) were measured at 24 h before anesthesia and 6 h,24 h, 48 h after anesthesia. Results: Compared with group S, the CPS in the group S+R was significantly increased(P〈0.05) at 6 h post-anesthesia; the PWT of bilateral hind paws of rats in the group S+R were significantly decreased(P〈0.05) at 24 h post-anesthesia.The PWT of the incision paw of rats in the group HPro+R was significantly increased(P〈0.05) as compared with that of the group Pro and group Pro+R at 6 h, 24 h, 48 h post-anesthesia. In addition, the CPS of the incision paw in group HPro+R was significantly lower than that of group Pro+R(P〈0.05) at 6 h, 24 h, 48 h post-anesthesia. Conclusions: Sevoflurane could exacerbate the remifentanil-induced postoperative hyperalgesia in rats, whole high dose of propofol could prevent it.
出处
《现代生物医学进展》
CAS
2016年第9期1615-1618,共4页
Progress in Modern Biomedicine
基金
湖南省社会发展支撑计划(2014SK3112)